JASN: The Next Chapter

Affiliations

Editorial

Rajnish Mehrotra. J Am Soc Nephrol. 2024.

. 2024 Jun 1;35(6):679-680.

doi: 10.1681/ASN.0000000000000378. Epub 2024 May 2.

¹ Division of Nephrology, Department of Medicine, University of Washington School of Medicine, Seattle, Washington.

No abstract available

Conflict of interest statement

Disclosure forms, as provided by each author, are available with the online version of the article at http://links.lww.com/JSN/E652.

1. Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, Zoccali C. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Nephrol Dial Transplant. 2019;34(11):1803–1805. doi:10.1093/ndt/gfz174 - DOI - PubMed
1. Tutunea-Fatan E Arumugarajah S Suri RS, et al. . Sensing dying cells in health and disease: the importance of kidney injury molecule-1. J Am Soc Nephrol. 2024;35(6):795–808. doi:10.1681/ASN.0000000000000334 - DOI - PMC - PubMed
1. Lee K, Drakas R, He JC. Small molecule allosteric inhibitor of HIPK2 as a novel therapy against kidney fibrosis. J Am Soc Nephrol. 2024;35(6):809–811. doi:10.1681/ASN.0000000000000327 - DOI - PMC - PubMed
1. Chatzimanouil MKT, Wilkens L, Anders HJ. Quantity and reporting quality of kidney research. J Am Soc Nephrol. 2019;30(1):13–22. doi:10.1681/ASN.2018050515 - DOI - PMC - PubMed
1. Leatherman SM, Ishani A. Point-of-care clinical trials in nephrology. J Am Soc Nephrol. 2024;35(6):812–814. doi:10.1681/ASN.0000000000000340 - DOI - PMC - PubMed